Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
25 hedge funds and large institutions have $645K invested in Statera Biopharma, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
32% more funds holding
Funds holding: 19 → 25 (+6)
10% less capital invested
Capital invested by funds: $715K → $645K (-$70K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$40.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.1K |
| 3 |
Walleye Trading
New York
|
+$11.7K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41K |
| 2 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.29K |
| 4 |
WA
Winfield Associates
Cleveland,
Ohio
|
-$1.15K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$423 |
STAB Hedge Fund Activity: Q4 2015 in Review
25 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2015, worth a combined $645K — down 9.8% from $715K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new STAB positions and 2 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $40.2K. The largest seller was Morgan Stanley, cutting an estimated $41K.
- 25 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2015, up from 19 in Q3 2015.
- Funds reported $645K of Statera Biopharma, Inc. Common Stock stock for Q4 2015, down 9.8% quarter-over-quarter.
- 8 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2015 and 2 closed out, a net change of +6 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2015 was Virtu KCG Holdings, an estimated $40.2K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2015 was Morgan Stanley, an estimated $41K sold.
Based on aggregated 13F filings for Q4 2015.